THE VALUE OF LDL-CHOLESTEROL AND HBA1C IN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AT TAM DUC HEART HOSPITAL
Main Article Content
Abstract
Background: LDL-cholesterol (LDL-C) plays a key role in the pathogenesis of coronary artery disease. In type 2 diabetes (T2D) patients, the disease tends to progress earlier and more severely, increasing the risk of major adverse cardiovascular events (MACEs). Objective: To evaluate the impact of LDL-C and glycemic control on MACEs after acute coronary syndrome (ACS) in patients with T2D. Methods: A retrospective cohort study was conducted on T2D patients hospitalized with ACS at Tam Duc Heart Hospital, Ho Chi Minh City, from January 1, 2021, to December 31, 2021. Results: A total of 177 patients were analyzed. After one year, 10 patients (5.6%) experienced MACEs. Only 24.9% achieved the LDL-cholesterol target and 20.3% achieved the HbA1C target. Patients who experienced MACEs had significantly higher HbA1C levels than event-free patients (p = 0.013). Although target attainment for LDL-C and HbA1C did not differ significantly between groups, the proportion with HbA1C > 8% was higher among those with MACEs (p = 0.041). Cox regression identified age and HbA1C > 8% as independent predictors of MACE (HR 4.657; 95% CI: 1.195–18.147; p = 0.027). Conclusion: Among T2D patients post-ACS, target attainment for LDL-C and HbA1C remained low. Age and HbA1C > 8% independently predicted MACEs, whereas LDL-C target attainment was not significantly associated with outcomes.
Article Details
Keywords
type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events
References
2. Casula M, Taietti I, Zeqaj I, et al. 386 Achieving Ldl Cholesterol Target In A Real-World Secondary Prevention Cohort: When Two Is Better Than One. European Heart Journal Supplements. 2020;22(Supplement_N):N132-N134. doi:10.1093/eurheartj/suaa207
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2019;41(1):111-188. doi:10.1093/ eurheartj/ehz455
4. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S17-S38. doi:10.2337/dc22-S002
5. Arnott C, Li Q, Kang A, et al. Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2020;9(3):e014908. doi:doi:10.1161/JAHA.119.014908
6. Yang HP, Weng SJ, Ho ZP, Xu YY, Liu SC, Tsai YT. A Comparison of Rehospitalization Risks on Diabetic and Non-Diabetic Patients after Recovery from Acute Coronary Syndrome. Healthcare (Basel). May 28 2022;10(6)doi:10.3390/healthcare10061003
7. Qiu W, Chen J, Huang X, Guo J. The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study. Lipids Health Dis. Jul 6 2020;19(1):163. doi:10.1186/s12944-020-01340-5
8. Farkouh ME, Godoy LC, Brooks MM, et al. Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. J Am Coll Cardiol. Nov 10 2020; 76(19): 2197-2207. doi:10.1016/j.jacc.2020.09.536